I-125 Versus Pd-103 for Medium Risk Prostate Cancer

Sponsored by VA Puget Sound Health Care System

Phase Quota
Phase 3

hypothesis: the shorter half-life of Pd-103 versus I-125, will increase the rate of tumor eradication. A total of 660 patients with AJC clinical stage T1c-T2a prostatic carcinoma (Gleason grade 7 to 9 and/or PSA 10â¿¿20 ng/ml) will be randomized to implantation with I-125 (144 Gy) versus Pd-103 (124 Gy).

Study Start Date: March 2003

Estimated Completion Date: Not specified

Specialties: Internal Medicine: Hematology/Oncology,Nephrology/Urology Nursing: Hematology/Oncology,Nephrology/Urology Urology: Oncology,Prostate Family Medicine: Men`s Health Oncology: Renal/Urologic


  • Procedure: I-125 versus Pd-103 radioactive seed insertion

Inclusion criteria

  • PSA 4-10 ng/ml
  • Gleason score 5 or 6

Exclusion criteria

  • N/A

Study Locations And Contact Information

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.